Literature DB >> 27456984

The cardiovascular risk management for people living with HIV in Europe: how well are we doing?

Maryam Shahmanesh1, Anna Schultze, Fiona Burns, Ole Kirk, Jens Lundgren, Cristina Mussini, Court Pedersen, Stephane De Wit, Galyna Kutsyna, Amanda Mocroft.   

Abstract

OBJECTIVES: HIV has become a chronic condition associated with comorbidities. We investigated cardiovascular risk and risk modification in a European HIV cohort.
METHODS: EuroSIDA patients (from 1 January 2000) for whom cardiovascular risk could be calculated (DAD risk equation) were included in the analysis. Moderate-to-high risk was defined as 5-year cardiovascular risk more than 5% and risk modification as two measurements meeting the European AIDS Clinical Society guidelines. Factors associated with risk development and modifications were investigated using Poisson regression.
RESULTS: Of 8762 individuals, 32.1% were hypertensive, 45.0% had high cholesterol, 47.4% were current smokers, and 27.1% were overweight. A total of 1504 (17.2%) had a 5-year cardiovascular risk of more than 5%. Of 7258 individuals with a 5-year risk less than 5%, 1905 (26.2%) developed cardiovascular risk more than 5% (6.53/100 person-years). These patients were more likely to be older, men, living in East Europe, with traditional cardiovascular risk factors. MSM with longer exposure to antiretroviral therapy, low CD4 nadir, higher current CD4 and prior AIDs events were more likely to develop cardiovascular risk. Those on antihypertensive treatment and living in central Europe were less likely to develop cardiovascular risk. Of those clinically indicated for risk modification, 1205 of 2077 (58.0%) successfully modified BP; 1283 of 3919 (32.8%) stopped smoking; 277 of 1394 (19.9%) modified cholesterol and 543 of 2163 (25.1%) reduced their BMI. There was variation in modification of individual risk factors, by sex, age, HIV-related factors and region of follow-up. Risk modification for BP and smoking improved over time (P < 0.001).
CONCLUSION: Cardiovascular risk was common. More than half modified their cardiovascular risk, and this improved over time.

Entities:  

Mesh:

Year:  2016        PMID: 27456984     DOI: 10.1097/QAD.0000000000001207

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC.

Authors:  M E Levy; A E Greenberg; R Hart; L Powers Happ; C Hadigan; A Castel
Journal:  HIV Med       Date:  2017-05-15       Impact factor: 3.180

Review 2.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

3.  Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Patient Care STDS       Date:  2018-02       Impact factor: 5.078

Review 4.  Epidemiology of ischemic heart disease in HIV.

Authors:  Virginia A Triant; Steven K Grinspoon
Journal:  Curr Opin HIV AIDS       Date:  2017-11       Impact factor: 4.283

5.  Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-27       Impact factor: 2.205

6.  Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study.

Authors:  Mikaela Smit; Rosan A van Zoest; Brooke E Nichols; Ilonca Vaartjes; Colette Smit; Marc van der Valk; Ard van Sighem; Ferdinand W Wit; Timothy B Hallett; Peter Reiss
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

7.  Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy.

Authors:  Rosan A van Zoest; Marc van der Valk; Ferdinand W Wit; Ilonca Vaartjes; Katherine W Kooij; Joppe W Hovius; Maria Prins; Peter Reiss
Journal:  Eur J Prev Cardiol       Date:  2017-06-05       Impact factor: 7.804

Review 8.  Recent 5-year Findings and Technological Advances in the Proteomic Study of HIV-associated Disorders.

Authors:  Lijun Zhang; Xiaofang Jia; Jun-O Jin; Hongzhou Lu; Zhimi Tan
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-06       Impact factor: 7.691

Review 9.  HIV and cardiovascular disease.

Authors:  Kaku So-Armah; Laura A Benjamin; Gerald S Bloomfield; Matthew J Feinstein; Priscilla Hsue; Benson Njuguna; Matthew S Freiberg
Journal:  Lancet HIV       Date:  2020-04       Impact factor: 16.070

Review 10.  Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV.

Authors:  Jack Edward Heron; Corinne Isnard Bagnis; David M Gracey
Journal:  AIDS Res Ther       Date:  2020-03-16       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.